Ambu A/S (LON:0MJF)
London · Delayed Price · Currency is GBP · Price in DKK | Market Cap | 1.92B -46.3% |
| Revenue (ttm) | 713.12M +4.6% |
| Net Income | 55.73M +28.9% |
| EPS | 0.21 +29.6% |
| Shares Out | n/a |
| PE Ratio | 34.40 |
| Forward PE | 23.35 |
| Dividend | 0.05 (0.08%) |
| Ex-Dividend Date | Dec 4, 2025 |
| Volume | 32,174 |
| Average Volume | 63,016 |
| Open | 63.15 |
| Previous Close | 62.50 |
| Day's Range | 62.40 - 63.38 |
| 52-Week Range | 60.73 - 111.80 |
| Beta | 1.26 |
| RSI | 39.00 |
| Earnings Date | May 6, 2026 |
About Ambu A/S
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products; and cardiology products comprising ECG electrodes. It also prov... [Read more]
Financial Performance
In fiscal year 2025, Ambu A/S's revenue was 6.04 billion, an increase of 11.98% compared to the previous year's 5.39 billion. Earnings were 609.00 million, an increase of 159.15%.
Financial numbers in DKK Financial StatementsNews
Q2 2026 Ambu A/S Earnings Call Transcript
Q2 2026 Ambu A/S Earnings Call Transcript
Ambu A/S Transcript: Q2 25/26
Endoscopy Solutions drove strong growth, offsetting A&PM declines, with guidance narrowed to 10%-12% revenue growth and EBIT margin maintained at 12%-14%. Share buyback expanded to DKK 450 million, and H2 is expected to see higher growth and margins.
Ambu A/S Transcript: Q1 25/26
Q1 delivered 8.6% organic revenue growth, led by endoscopy (14.4%) and strong urology/respiratory momentum. EBIT margin was 10.5% (adjusted >15% excluding tariffs/FX), with full-year guidance maintained and tariff/FX headwinds expected to ease in H2.
Ambu A/S Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong double-digit growth and a successful turnaround have positioned the company as a leader in single-use endoscopy, with a focus on respiratory and urology. Innovation, scalable operations, and a robust financial outlook support continued expansion, while competition and market conversion drive future growth.
Ambu A/S Transcript: Q4 24/25
Delivered 13.1% organic revenue growth and 13.0% EBIT margin, driven by strong endoscopy and anesthesia segments. Outlook for 2025-2026 is 10%-13% organic growth and 12%-14% EBIT margin, with tariffs and FX as key headwinds but long-term targets reaffirmed.
Ambu A/S Transcript: CMD 2025
A new growth strategy targets global endoscopy leadership through single-use innovation, digital solutions, and operational scale. Financial guidance is raised to 11%-13% organic CAGR and 20%+ EBIT margin by 2029/30, with disciplined M&A and a strong focus on people, sustainability, and customer-centricity.
Ambu A/S Transcript: Q3 24/25
Q3 delivered strong organic growth and margin expansion, with guidance raised for full-year revenue. FX headwinds and higher working capital impacted margins and cash flow, but operational leverage and new product launches support a positive outlook.
Ambu A/S Transcript: Q2 24/25
Delivered 15.4% organic revenue growth in the first half and 11.7% in Q2, with EBIT margin at 14.4% for the quarter. Maintains full-year guidance despite tariff and currency risks, supported by strong product launches and manufacturing flexibility.
Ambu A/S Transcript: Q1 24/25
Q1 saw 19.5% organic revenue growth and a 16.1% EBIT margin, driven by strong performance in Endoscopy Solutions and Anesthesia/Patient Monitoring. Guidance for the year was raised, with new product launches and operational efficiencies supporting future growth.
Ambu A/S Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025
Endoscopy solutions achieved nearly 20% growth and now comprise 60% of revenue, with strong gains in pulmonology, urology, and ENT. New product launches and a unified software platform support continued leadership, while operational improvements and a debt-free position enable investment in growth. Guidance was raised following a robust Q1.
Ambu A/S Transcript: Q4 23/24
Q4 and full-year revenue grew strongly, led by endoscopy, with improved margins and robust cash flow. Guidance for 2024-2025 targets 10%-13% organic growth and 12%-14% EBIT margin, supported by new product launches and continued momentum, despite some risks in ANPM and GI segments.
Ambu A/S Transcript: Q3 23/24
Q3 delivered 15% organic revenue growth, margin expansion, and strong cash flow, led by Endoscopy Solutions and price-driven gains in Anesthesia and Patient Monitoring. New product approvals and sustainability initiatives support future growth, with upgraded full-year guidance and ongoing investments in commercial and IT infrastructure.
Ambu A/S Transcript: Q2 23/24
Ambu A/S Transcript: Q1 23/24
Ambu A/S Transcript: Q4 22/23
ANNUAL REPORT 2022/23 (EARNINGS RELEASE)
For the full 2022/23 financial year, Ambu reported 7.6% organic revenue growth. This was driven by Endoscope Solutions posting 15% organic growth, the main drivers being urology and ENT growing high d...
Ambu A/S Transcript: Q3 22/23
Ambu A/S Transcript: Q2 22/23
Ambu A/S Transcript: CMD 2023
Ambu A/S Transcript: Q1 22/23
Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S...